Company intelligence / Profile preview
Egret Therapeutics
New York, New York, United Statesegrettherapeutics.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Clinical
01
Overview
Egret Therapeutics is advancing to Phase II trials for their lead indication, Malignant Cerebral Edema. They received FDA clearance for their IND application for EGT 101 for the treatment of Delayed Cerebral Ischemia (DCI) following aneurysmal subarachnoid hemorrhage in February 2023, with Phase I/II trials expected to begin enrolling patients in 2023[4].
- Therapeutic areas
- OncologyCardiovascularNeurologyOther
- Modalities
- Biotherapeutics
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Egret Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Egret Therapeutics.